ANYONE LOSING HERE THIS IS FOR YOU! READ TO THE END
$Allarity Therapeutics (ALLR.US)$ NEW YORK, Aug. 23, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company").
The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
On July 22, 2024, before the U.S. stock markets opened for trading, Allarity filed a current report on Form 8-K, in which the Company disclosed that: "Allarity Therapeutics, Inc. (the 'Company') received a 'Wells Notice' from the Staff of the U.S. Securities and Exchange Commission (the 'SEC') relating to the Company's previously disclosed SEC investigation."
Allarity also revealed that "[t]he Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the 'FDA') regarding the Company's NDA [New Drug Application] for Dovitinib or Dovitinib-DRP," and that "Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct." Further,"[t]he Wells Notice informed the Company that the SEC Staff had made a preliminarydetermination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws."
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville, and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
On July 22, 2024, before the U.S. stock markets opened for trading, Allarity filed a current report on Form 8-K, in which the Company disclosed that: "Allarity Therapeutics, Inc. (the 'Company') received a 'Wells Notice' from the Staff of the U.S. Securities and Exchange Commission (the 'SEC') relating to the Company's previously disclosed SEC investigation."
Allarity also revealed that "[t]he Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the 'FDA') regarding the Company's NDA [New Drug Application] for Dovitinib or Dovitinib-DRP," and that "Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct." Further,"[t]he Wells Notice informed the Company that the SEC Staff had made a preliminarydetermination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws."
Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville, and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly lauded by the courts, which have appointed it to major positions in complex securities, multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Daight : huh didn't you shared this?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Daight : Yes July 31st! But since the PR was released again this morning. I figured i would pass it along for those who may not have seen? Or to give a reminder. Or for newer people
Daight Trytosaveabit OP : ah I see
买跌不追涨 : Do investors need to contact this company to cooperate with the lawsuit to receive compensation? What kind of compensation is used? cash?
Trytosaveabit OP 买跌不追涨 : Yes contact them and they will probably add your information to the, I imagine will be a Class Action Suit?
买跌不追涨 Trytosaveabit OP : I don't have this stock, just wanted to know
Trytosaveabit OP 买跌不追涨 : That’s fine! You don’t have to have the ticker to ask me anything! Ifn I can help / answer? I will gladly try.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
KSOL Trytosaveabit OP : thanks!
simply put, there was a problem? we should contact the company for what purpose?